Overview

Comparison of Interval Variation and Dosage in Preoperative Bevacizumab and Ziv-Aflibercept Administration in Proliferative Diabetic Retinopathy Undergoing Vitrectomy

Status:
Recruiting

Trial end date:
2023-10-01

Target enrollment:

Participant gender:

Summary

To compare outcomes in subjects receiving different doses and treatment intervals of intravitreal bevacizumab or ziv-aflibercept preoperatively administered prior to undergoing vitrectomy for complications of proliferative diabetic retinopathy.

Phase:

N/A

Details

Lead Sponsor:

Panhandle Eye Group, LLP

Treatments:

Aflibercept
Bevacizumab